Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current landscape of sequencing ADCs in metastatic breast cancer.
McLaughlin S, Ravani LV, Moy B, Medford AJ, Isakoff SJ, Liu T, Ellisen LW, Spring LM, Wander SA, Abelman RO. McLaughlin S, et al. Among authors: spring lm. Ther Adv Med Oncol. 2025 Dec 17;17:17588359251396656. doi: 10.1177/17588359251396656. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 41424607 Free PMC article. Review.
Selection biases in the systematic collection of breast biobank specimens.
Bar Y, Wang GX, Gioia GE, Fell G, Chou SS, Bossuyt V, Isakoff SJ, Moy B, Ellisen LW, Lehman CD, Spring LM. Bar Y, et al. Among authors: spring lm. NPJ Breast Cancer. 2025 Aug 1;11(1):83. doi: 10.1038/s41523-025-00798-9. NPJ Breast Cancer. 2025. PMID: 40750597 Free PMC article.
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
Medford AJ, Velimirovic M, Gefen Y, Niemierko A, Gerratana L, Davis AA, Clifton K, Keenan J, Podany E, Hensing WL, Reduzzi C, Dai CS, Kiedrowski LA, Spring LM, Ellisen LW, Doebele RC, Cristofanilli M, Getz G, Bardia A. Medford AJ, et al. Among authors: spring lm. Breast Cancer Res Treat. 2025 Aug;212(3):437-447. doi: 10.1007/s10549-025-07710-w. Epub 2025 May 29. Breast Cancer Res Treat. 2025. PMID: 40439821 Free PMC article.
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Spring LM, Scarpetti L, Medford AJ, Niemierko A, Comander A, Mulvey T, Schnipper L, Isakoff SJ, Moy B, Wander SA, Shin J, Ephrem Z, Laposta AR, Denault E, Abraham E, Calistro G, Kalashnikova E, Rodriguez A, Liu MC, Aleshin A, Peppercorn J, Ellisen LW, Bardia A. Spring LM, et al. NPJ Breast Cancer. 2025 Jan 7;11(1):2. doi: 10.1038/s41523-024-00708-5. NPJ Breast Cancer. 2025. PMID: 39774684 Free PMC article.
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, Bitman E, Thant W, Liu T, Weipert C, Fell G, Spring LM, Wander SA, Moy B, Vidula N, Isakoff SJ, Varkaris A, Juric D, Corcoran RB, Ellisen LW, Bardia A. Abelman RO, et al. Among authors: spring lm. Clin Cancer Res. 2025 May 15;31(10):1966-1974. doi: 10.1158/1078-0432.CCR-24-2771. Clin Cancer Res. 2025. PMID: 39745368 Free PMC article.
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
Li Z, Metzger Filho O, Viale G, dell'Orto P, Russo L, Goyette MA, Kamat A, Yardley DA, Gupta Abramson V, Arteaga CL, Spring LM, Chiotti K, Halsey C, Waks AG, King TA, Lester SC, Bellon JR, Winer EP, Spellman PT, Krop IE, Polyak K. Li Z, et al. Among authors: spring lm. J Clin Invest. 2024 Feb 1;134(7):e176454. doi: 10.1172/JCI176454. J Clin Invest. 2024. PMID: 38300710 Free PMC article. Clinical Trial.
64 results